文献速递类风湿关节炎

抑制miR-106b减轻胶原诱导性关节炎的炎症反应与关节破坏

Downregulation of miR-106b attenuates inflammatory responses and joint damage in collagen-induced arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究在CIA小鼠中通过慢病毒介导的miR-106b抑制剂干预,发现抑制miR-106b可降低关节炎发病率、减轻骨破坏和组织学严重程度,并抑制RANKL表达、升高OPG、降低RANKL:OPG比值及炎症因子水平,提示miR-106b可能成为RA治疗靶点。

要点

  • CIA小鼠中miR-106b表达升高,与骨丢失和炎症浸润相关。
  • miR-106b抑制剂降低关节炎发病率并减轻骨破坏与组织学严重程度。
  • 抑制miR-106b降低RANKL:OPG比值及炎症因子,减少破骨细胞分化。

核心结论

  • 抑制miR-106b可改善CIA相关炎症与骨破坏,可能成为人RA的潜在治疗靶点。

研究设计与样本

  • 研究在DAB/1小鼠中注射含弗氏佐剂的牛II型胶原建立CIA模型,于第22天起每周经眶后注射慢病毒阴性对照、miR-106b mimics或miR-106b inhibitor。

主要发现

  • CIA小鼠miR-106b表达升高,并出现CIA相关骨丢失和炎症浸润。
  • 与对照组相比,miR-106b抑制剂治疗显著降低关节炎发病率、减轻骨破坏和组织学严重程度。
  • miR-106b抑制剂抑制RANKL表达、增加OPG表达并降低CIA小鼠的RANKL:OPG比值。
  • miR-106b抑制显著减少关节切片炎症介质产生并降低血清促炎细胞因子水平。
  • miR-106b抑制减少抗酒石酸酸性磷酸酶阳性细胞数量并抑制小鼠骨髓巨噬细胞分化。

临床怎么用

  • 该研究为动物实验,提示miR-106b抑制可能作为RA抗炎与抗骨破坏的潜在策略,尚需人体研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: miRNAs are small, signal-strand, non-coding RNAs that function in post-transcriptional regulation. We analysed the in vivo effect of miR-106b (miR-106b-5p) on inflammatory bone loss in CIA mice. METHODS: CIA mice are developed by injecting DAB/1 mice with bovine type II collagen containing Freund's adjuvant and then the in vivo effect of miR-106b is examined. On day 22, mice were given lentiviral negative control, lentiviral-mediated miR-106b mimics or lentiviral-mediated miR-106b inhibitor via orbital injection on a weekly basis. Morphological changes in the ankle joints were assessed via micro-CT and histopathology and cytokine expression levels were examined via immunohistochemical staining, ELISA or flow cytometric analysis. miR-106b and osteoclastic-related gene expression was evaluated via quantitative real-time PCR. RESULTS: CIA mice were found to have increased miR-106b expression and CIA-associated bone loss and inflammatory infiltration. miR-106b inhibitor treatment markedly decreased arthritis incidence and attenuated bone destruction and histological severity compared with the control group. Moreover, miR-106b inhibitor treatment suppressed RANK ligand (RANKL) expression, increased osteoprotegerin (OPG) expression and reduced the RANKL:OPG ratio in CIA mice. miR-106b inhibition also significantly decreased inflammatory mediator production in joint sections and reduced serum pro-inflammatory cytokine levels when compared with the control group. Additionally, miR-106b inhibition decreased tartrate-resistant acid phosphatase-positive cell numbers and suppressed murine bone marrow macrophage differentiation. CONCLUSION: These findings indicate that miR-106b inhibition can ameliorate CIA-associated inflammation and bone destruction and thus may serve as a potential therapeutic for human RA treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tao Y, Wang Z, Wang L, et al. Downregulation of miR-106b attenuates inflammatory responses and joint damage in collagen-induced arthritis. Rheumatology (Oxford). 2017. PMID: 28957555. doi:10.1093/rheumatology/kex233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。